Cover Image

A SWOT‐Consensus for CAR‐T in Follicular Lymphoma: Fine Tuning of Patient Journey and Selection

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Monia Marchetti, Paolo Corradini, Luca Arcaini, Stefania Bramanti, Alice Di Rocco, Marco Ladetto, Stefano Luminari, Luigi Rigacci, Pier Luigi Zinzani
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	Hematological Oncology
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Unmet needs in relapsed/refractory mantle cell lymphoma after failure of covalent Bruton's tyrosine kinase inhibitors: An Italian scenario
by: Antonio Pinto, et al.
Published: (2024)

Review of the Management of Relapsed/Refractory Follicular Lymphoma: An Italian Perspective
by: Giacomo Loseto, et al.
Published: (2025)

Polatuzumab Vedotin and Glofitamab for Relapsed/Refractory Diffuse Large B‐Cell Lymphoma in the Compassionate Use Program in Italy
by: Pier Luigi Zinzani, et al.
Published: (2025)

Identifying and addressing unmet clinical needs on the use of zanubrutinib in chronic lymphocytic leukemia: A consensus‐based position paper from an ad hoc expert panel
by: Francesca Romana Mauro, et al.
Published: (2024)

350 | PATIENTS WITH RELAPSED/REFRACTORY PMBCL HAVE BETTER SURVIVAL WHEN THE SALVAGE STRATEGY INCLUDES CAR T‐CELLS: AN ANALYSIS OF THE REPRIME‐FIL AND THE CART‐SIE STUDIES
by: A. Guidetti, et al.
Published: (2025)

Genetic and Transcriptomic Profiles Identify Potential Therapeutic Targets of Concurrent Follicular and Diffuse Large B‐Cell Lymphoma and Transformed Follicular Lymphoma
by: Rui Sun, et al.
Published: (2026)

Follicular Lymphoma: Current Therapeutic Landscape and Future Prospects
by: Emil Kumar, et al.
Published: (2025)

Real‐life study on the use of response adapted therapy in patients with Hodgkin Lymphoma: Results from a multicenter experience
by: Vittorio Ruggero Zilioli, et al.
Published: (2024)

Role of gut microbiome in the outcome of lymphoma patients treated with checkpoint inhibitors—The MicroLinf Study
by: Beatrice Casadei, et al.
Published: (2024)

Managing Treatment‐Emergent Immune Effector Cell‐Associated Hemophagocytic Lymphohistiocytosis‐Like Syndrome Following CAR‐T Cell Therapy: A Case‐Based Review of the use of Emapalumab
by: Livia Donzelli, et al.
Published: (2025)

Combining Total Metabolic Tumor Volume With Beta‐2‐Microglobulin Levels Predicts Outcomes in High‐Burden Follicular Lymphoma Patients
by: A. Zduniak, et al.
Published: (2024)

Different Role of PET‐CT Evaluation in Newly Diagnosed Follicular Lymphoma Upon Rituximab‐Based Chemotherapy and Chemo‐Free Immunotherapy
by: Nan Wang, et al.
Published: (2024)

Survival Benefit of Relmacabtagene Autoleucel Versus Usual Care in Relapsed/Refractory Follicular Lymphoma: A Matching‐Adjusted Indirect Analysis
by: Fenghua Gao, et al.
Published: (2025)

Comparative Effectiveness of R‐miniCOMP Versus R‐miniCHOP in Older Non‐Fit Patients With Diffuse Large B‐Cell Lymphoma: Insights From a “Fondazione Italiana Linfomi” Cohort Study
by: Alberto Bavieri, et al.
Published: (2025)

Outcomes of Bridging Therapy in Patients With Relapsed/Refractory Large B Cell Lymphoma Receiving Third‐Line CAR T
by: Inna Y. Gong, et al.
Published: (2026)

Post‐CAR T‐Cell Therapy Failure Metabolic Parameters Predict Survival and Response in Large B‐Cell Lymphoma
by: Hazim S. Ababneh, et al.
Published: (2024)

Routine Monitoring of CAR‐T‐Cells Expansion and Persistence in Patients With Aggressive Large B‐Cell Lymphoma by Flow Cytometry: A Single‐Center Experience
by: Alexandra Zduniak, et al.
Published: (2025)

136 | MINIMAL RESIDUAL DISEASE WITH BENDAMUSTINE‐RITUXIMAB WITH OR WITHOUT ACALABRUTINIB IN PATIENTS WITH PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA: RESULTS FROM THE ECHO TRIAL
by: P. L. Zinzani, et al.
Published: (2025)

Clinical Outcomes of CD7 CAR‐T Cell Therapy in Relapsed or Refractory T‐Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Patients
by: Jinyan Xiao, et al.
Published: (2025)

409 | EARLY IDENTIFICATION OF CAR T‐CELL THERAPY NON‐RESPONDERS IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA USING FDG‐PET QUANTITATIVE PARAMETERS
by: C. Pellegrini, et al.
Published: (2025)

CAR T‐Cell Therapies for Patients With Relapsed and Refractory Aggressive Lymphomas: Real‐World Experiences From a Single Center on the Use of Radiotherapy
by: J.T. Jutzi, et al.
Published: (2025)

Baseline Tumor Burden Assessed With AI‐Guided PET/CT Total Metabolic Tumor Volume (TMTV) and LDH Levels Predict Efficacy of CAR‐T in Aggressive B‐Cell Lymphoma
by: Eugenio Galli, et al.
Published: (2024)

VEGF as a Relapse Marker and an Intensity of Disease Marker in Patients Affected by POEMS Syndrome Treated With Autologous Peripheral Blood Stem Cell Transplantation
by: Francesco Autore, et al.
Published: (2025)

850 | GOLSEEK‐2: A PHASE 2 RANDOMIZED, OPEN‐LABEL STUDY OF GOLCADOMIDE IN COMBINATION WITH RITUXIMAB IN PARTICIPANTS WITH NEWLY DIAGNOSED ADVANCED‐STAGE FOLLICULAR LYMPHOMA
by: P. Luigi Zinzani, et al.
Published: (2025)

855 | A PHASE 3 RANDOMIZED TRIAL: DUVELISIB VERSUS INVESTIGATOR CHOICE (GEMCITABINE OR BENDAMUSTINE) IN RELAPSED/REFRACTORY NODAL T‐CELL LYMPHOMA WITH T‐FOLLICULAR HELPER PHENOTYPE
by: K. Cwynarski, et al.
Published: (2025)

RETRACTION: Burkitt Lymphoma Versus Diffuse Large B‐Cell Lymphoma: A Practical Approach
Published: (2026)

Ibrutinib Dose Adjustment Does Not Impair Treatment Outcome in Mantle Cell Lymphoma: An Italian Real‐Life Multicenter Experience. Results From the REDOT_MCL Study
by: Francesca Maria Quaglia, et al.
Published: (2026)

57 | CLONAL HEMATOPOIESIS IN FOLLICULAR LYMPHOMA: ANALYSIS OF THE PHASE III FIL FOLL12 TRIAL
by: R. Moia, et al.
Published: (2025)

133 | LONG‐TERM SURVIVAL TRENDS IN ADVANCED‐STAGE MANTLE CELL LYMPHOMA: A POOLED ANALYSIS OF SIX RANDOMIZED PHASE III TRIALS FROM 1996 TO 2020
by: L. Jiang, et al.
Published: (2025)

861 | BRIDGING RADIATION THERAPY IN CAR‐T THERAPY
by: T. Li, et al.
Published: (2025)

Peripheral T‐Cell Lymphoma: What's Next?
by: Sang Eun Yoon, et al.
Published: (2025)

Current Status of Revisions to the Lugano Classification in Lymphoma
Published: (2025)

657 | TRANSPLANTATION IN COMBINATION WITH CAR‐T THERAPY FOR REFRACTORY/RELAPSED AGGRESSIVE B‐CELL LYMPHOMA AFTER FAILURE OF CD19 CAR‐T CELL THERAPY
by: F. Yang, et al.
Published: (2025)

Clinicopathological Characteristics of Extranodal Marginal Zone Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT‐Lymphoma) of the Intestine: A Single Center Analysis
by: Oskar Steinbrecher, et al.
Published: (2024)

Multiple Myeloma Unpacked
by: Francesca Gay, et al.
Published: (2025)

Lomustine, Etoposide and Cyclophosphamide as Conditioning for Auto‐HCT in Lymphomas
by: Rafaella Cabral Samico, et al.
Published: (2025)

847 | PALT TRIAL: FIRST IN CLASS GLYCO‐HUMANIZED POLYCLONAL ANTIBODY DIRECTED AGAINST TUMORAL T CELLS, IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T CELLS LYMPHOMA
by: G. Damaj, et al.
Published: (2025)

778 | THE IMPORTANCE OF INFLAMMATORY BIOMARKERS IN PREDICTING RESPONSE TO CAR‐T IN PATIENTS WITH LYMPHOMA
by: N. De Lucas Torres, et al.
Published: (2025)

780 | DEATHS IN PATIENTS IN COMPLETE REMISSION WITH CAR T THERAPY. TOXICITY INTO ACCOUNT?
by: S. Sequero Lopez, et al.
Published: (2025)

Breaking Traditions: Evaluating Single Fraction Radiation in Indolent Lymphoma
by: Hazim S. Ababneh, et al.
Published: (2024)